Holen Sie sich die Stockscreener-App
17.78
2.72%
0.47
Vorhandelsmarkt:
17.73
-0.05
-0.28%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$17.31
Offen:
$17.57
24-Stunden-Volumen:
5.34M
Relative Volume:
0.57
Marktkapitalisierung:
$9.18B
Einnahmen:
$11.32B
Nettoeinkommen (Verlust:
$-981.00M
KGV:
-9.103
EPS:
-1.9532
Netto-Cashflow:
$714.00M
1W Leistung:
+1.66%
1M Leistung:
+1.08%
6M Leistung:
-3.74%
1J Leistung:
-41.36%
1-Tages-Spanne:
$17.39
$17.98
1-Wochen-Bereich:
$17.09
$18.09
52-Wochen-Spanne:
$15.73
$32.04
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
17.78 | 8.94B | 11.32B | -981.00M | 714.00M | -1.9532 |
ISRG
Intuitive Surgical Inc
|
428.06 | 153.09B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.47 | 39.73B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
38.90 | 32.73B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.00 | 30.94B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
202.46 | 29.36B | 5.54B | 1.52B | 1.74B | 10.37 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International stock (US0673431090): Gains 2.05% to $17.89 - AD HOC NEWS
Baxter International Inc. stock (US0673431090): Down 3.2% amid conference presentation - AD HOC NEWS
Baxter International stock outlook: Is Wall Street bullish or bearish? - MSN
First Pacific Advisors' Strategic Moves: Baxter International Inc. Takes Center Stage - GuruFocus
BofA Securities Maintains Baxter International Inc(BAX.US) With Hold Rating, Maintains Target Price $24 - 富途牛牛
Baxter International Inc (BAX) Stock Down 3.2% -- Now Undervalued? GF Score: 66/100 - GuruFocus
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Transcript : Baxter International Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 11 - marketscreener.com
Baxter International Inc. stock (US0673431090): Recent 2% price gain on NYSE - AD HOC NEWS
Baxter International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Baxter International Inc stock (US0718131099): Shares drop 2.56% to $17.53 - AD HOC NEWS
Baxter International earnings preview: What to expect - MSN
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Rare Hemophilia Factors Market Is Going to Boom |• Baxter International • Novo Nordisk • Pfizer - openPR.com
Baxter International Inc. stock (US0673431090): Q1 2026 earnings beat consensus - AD HOC NEWS
Precision Trading with Baxter International Inc. (BAX) Risk Zones - Stock Traders Daily
Baxter International shareholders approve board slate, pay and incentive plan at annual meeting - MSN
Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting - Barchart.com
Baxter International Inc. stock (US0673431090): Governance shake?up and earnings pressure in focus - AD HOC NEWS
Baxter Updates Executive Severance Plan and Governance Framework - TipRanks
Baxter International updates executive severance plan and amends bylaws after annual meeting - Investing.com
Baxter (NYSE: BAX) expands severance protections and adds 20M incentive shares - Stock Titan
Infusion Therapy Market Is Going to Boom | Baxter International, B. Braun Melsungen AG, Fresenius Kabi AG - openPR.com
BAX Stock Price, Quote & Chart | BAXTER INTERNATIONAL INC (NYSE:BAX) - ChartMill
Baxter International Still Has A Path To Upside - Seeking Alpha
Director at Baxter (NYSE: BAX) receives 12,836 fully vested share award, now holds 37,076 - Stock Titan
Baxter (BAX) director Amy McBride receives 12,836-share fully vested stock grant - Stock Titan
Director at Baxter (NYSE: BAX) awarded 12,836 shares, holds 34,994 - Stock Titan
Baxter International (BAX) director awarded 12,836 fully vested shares - Stock Titan
Baxter (BAX) board chair David Brent Shafer receives 12,836-share stock grant - Stock Titan
Director Michael McDonnell of Baxter (NYSE: BAX) receives 12,836-share fully vested grant - Stock Titan
Director Jeffrey A. Craig receives 12,836 Baxter (BAX) shares in grant - Stock Titan
Baxter (NYSE: BAX) director awarded 12,836 fully vested shares in Form 4 - Stock Titan
MSN Money - MSN
Becton Dickinson at 13x Earnings: MedTech’s Most Mispriced Compounder - Investing.com
Baxter International Inc. stock rises Wednesday, still underperforms market - MarketWatch
FMR LLC reports 9.0% stake in Baxter International (BAX) — 46.3M shares - Stock Titan
Assessing Baxter International’s Valuation After Earnings Beat And Guidance Reaffirmation - simplywall.st
Pheochromocytoma Market to Reach USD 3.86 Billion by 2033 at 8.5% - openPR.com
Franklin Mutual U.S. Mid Cap Value Fund's Baxter International Inc(BAX) Holding History - GuruFocus
The Adirondack Small Cap Fund's Baxter International Inc(BAX) Holding History - GuruFocus
Baxter International Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart.com
Barclays Maintains Baxter International Inc(BAX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Baxter International Inc. (BAX) Stock Analysis: Exploring a 28.5% Potential Upside for Healthcare Investors - DirectorsTalk Interviews
Research Alert: CFRA Keeps Hold Rating On Shares Of Baxter International Inc. - 富途牛牛
Baxter International 1Q Loss $15M >BAX - Moomoo
Assessing Baxter International (BAX) Valuation After Earnings Beat And Reaffirmed Outlook - Yahoo Finance
Baxter International Inc. (NYSE:BAX) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
Baxter International (BAX) Is Down 5.2% After Q1 Loss But Turnaround Guidance ReaffirmedWhat's Changed - Yahoo Finance
Baxter Profit Plunges 35% As Tariffs, Costs Bite - Sahm
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):